MaxCyte

About:

MaxCyte specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes.

Website: http://www.maxcyte.com/

Twitter/X: maxcyte_info

Top Investors: Harbert Growth Partners, Intersouth Partners, Tall Oaks Capital Partners

Description:

MaxCyte specializes in cell modification technologies that enable the discovery, development, and manufacture of various classes of therapeutics for a range of chronic and acute diseases. It provides MaxCyte STX, a scalable transfection system for the scalable and reagent-free (co) transfection of primary cells, stem cells, and cell lines involved in the areas of cell-based assays for content screening, preclinical protein production, and small molecule.

Total Funding Amount:

$30.5M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Gaithersburg, Maryland, United States

Founded Date:

1998-01-01

Contact Email:

info(AT)maxcyte.com

Founders:

John W Holaday

Number of Employees:

11-50

Last Funding Date:

2014-12-16

IPO Status:

Public

Industries:

© 2025 bioDAO.ai